Defender Pharmacuticals, Inc. (DPI) is a development-stage pharmaceutical organization focused on the discovery, development, and partnering of anti-emetic (anti-vomiting and anti-nausea) compounds for both the human and veterinary markets.The primary focus of DPI is the development of scopolamine as a motion sickness countermeasure, specifically in the military and for astronauts, filling a large unmet need for an easily-administered, fast-acting motion sickness remedy, and can lead to life-threatening and mission-threatening debilitation.
Product Categories
- Medical